ZA923942B - Quinuclidine derivatives - Google Patents

Quinuclidine derivatives

Info

Publication number
ZA923942B
ZA923942B ZA923942A ZA923942A ZA923942B ZA 923942 B ZA923942 B ZA 923942B ZA 923942 A ZA923942 A ZA 923942A ZA 923942 A ZA923942 A ZA 923942A ZA 923942 B ZA923942 B ZA 923942B
Authority
ZA
South Africa
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
Prior art date
Application number
ZA923942A
Other languages
English (en)
Inventor
Fumitaka Ito
Kaoru Shimada
John A Lowe Iii
Hiroshi Kondo
Masami Nakane
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA923942(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ZA923942B publication Critical patent/ZA923942B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA923942A 1991-05-31 1992-05-29 Quinuclidine derivatives ZA923942B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31

Publications (1)

Publication Number Publication Date
ZA923942B true ZA923942B (en) 1993-11-29

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923942A ZA923942B (en) 1991-05-31 1992-05-29 Quinuclidine derivatives

Country Status (41)

Country Link
US (3) US5807867A (cg-RX-API-DMAC7.html)
EP (1) EP0587723B1 (cg-RX-API-DMAC7.html)
JP (2) JPH0733386B2 (cg-RX-API-DMAC7.html)
KR (1) KR100214905B1 (cg-RX-API-DMAC7.html)
CN (1) CN1048492C (cg-RX-API-DMAC7.html)
AP (1) AP299A (cg-RX-API-DMAC7.html)
AT (1) ATE135006T1 (cg-RX-API-DMAC7.html)
AU (1) AU657552B2 (cg-RX-API-DMAC7.html)
BG (1) BG61694B1 (cg-RX-API-DMAC7.html)
BR (1) BR9206073A (cg-RX-API-DMAC7.html)
CA (1) CA2102179C (cg-RX-API-DMAC7.html)
CZ (1) CZ281403B6 (cg-RX-API-DMAC7.html)
DE (4) DE122006000066I1 (cg-RX-API-DMAC7.html)
DK (1) DK0587723T3 (cg-RX-API-DMAC7.html)
EG (1) EG19944A (cg-RX-API-DMAC7.html)
ES (1) ES2084361T3 (cg-RX-API-DMAC7.html)
FI (1) FI114475B (cg-RX-API-DMAC7.html)
GR (1) GR3019687T3 (cg-RX-API-DMAC7.html)
GT (1) GT199200028A (cg-RX-API-DMAC7.html)
HU (1) HU217548B (cg-RX-API-DMAC7.html)
IE (1) IE72473B1 (cg-RX-API-DMAC7.html)
IL (1) IL102008A (cg-RX-API-DMAC7.html)
IS (1) IS1611B (cg-RX-API-DMAC7.html)
LU (1) LU91293I2 (cg-RX-API-DMAC7.html)
MA (1) MA22539A1 (cg-RX-API-DMAC7.html)
MX (1) MX9202554A (cg-RX-API-DMAC7.html)
NL (1) NL300250I2 (cg-RX-API-DMAC7.html)
NO (2) NO302701B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ270673A (cg-RX-API-DMAC7.html)
OA (1) OA09867A (cg-RX-API-DMAC7.html)
PL (1) PL171379B1 (cg-RX-API-DMAC7.html)
PT (1) PT100546B (cg-RX-API-DMAC7.html)
RO (1) RO110499B1 (cg-RX-API-DMAC7.html)
RU (1) RU2103269C1 (cg-RX-API-DMAC7.html)
SK (1) SK390692A3 (cg-RX-API-DMAC7.html)
TW (1) TW204349B (cg-RX-API-DMAC7.html)
UA (1) UA27776C2 (cg-RX-API-DMAC7.html)
UY (1) UY23422A1 (cg-RX-API-DMAC7.html)
WO (1) WO1992021677A1 (cg-RX-API-DMAC7.html)
YU (1) YU48995B (cg-RX-API-DMAC7.html)
ZA (1) ZA923942B (cg-RX-API-DMAC7.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA27776C2 (uk) * 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
AU657967B2 (en) * 1991-06-20 1995-03-30 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
JP2909214B2 (ja) * 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
EP1061926A2 (en) * 1998-03-19 2000-12-27 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use as tachykinin receptor antagonists
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CN1414953A (zh) 1999-11-03 2003-04-30 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和5－羟色胺重摄取的用途
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
PT1592384E (pt) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
WO2005043153A1 (en) * 2003-10-27 2005-05-12 Meyer Donald W Transmissible spongiform encephalopathy detection in cervids, sheep and goats
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
JP2007519701A (ja) * 2004-01-30 2007-07-19 ファイザー・プロダクツ・インク 麻酔回復を改善するためのｎｋ−１受容体拮抗剤
CA2554360A1 (en) * 2004-02-02 2005-08-18 Pfizer Products Inc. Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
CN101119969B (zh) 2004-07-15 2014-04-09 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2805945T3 (pl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
JP5764553B2 (ja) 2009-05-12 2015-08-19 アルバニー モレキュラー リサーチ， インコーポレイテッド ７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンおよびその使用
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
NO2729147T3 (cg-RX-API-DMAC7.html) 2011-07-04 2018-02-03
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
UA27776C2 (uk) * 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
EP0919245A3 (en) * 1991-09-20 2000-11-15 Glaxo Group Limited NK-1 receptor antagonist and a systemic antiinflammatory corticosteroid for the treatment of emesis
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DK0785198T3 (da) * 1996-01-19 2000-11-13 Lonza Ag Fremgangsmåde til fremstilling af optisk aktiv 3-quinuclidinol
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
BG98248A (bg) 1994-07-29
CN1067428A (zh) 1992-12-30
CA2102179A1 (en) 1992-12-01
JPH06504292A (ja) 1994-05-19
PT100546A (pt) 1993-08-31
IS3871A (is) 1992-12-02
SK278788B6 (sk) 1998-02-04
FI935297L (fi) 1993-11-29
NO2007003I2 (no) 2011-04-18
EG19944A (en) 1997-02-27
NZ242956A (en) 1995-06-27
NO302701B1 (no) 1998-04-14
AU657552B2 (en) 1995-03-16
GR3019687T3 (en) 1996-07-31
NO934312D0 (no) 1993-11-29
DE69208877D1 (de) 1996-04-11
US5939433A (en) 1999-08-17
AU1990192A (en) 1993-01-08
NO934312L (no) 1993-11-29
JPH0733386B2 (ja) 1995-04-12
UA27776C2 (uk) 2000-10-16
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
MA22539A1 (fr) 1992-12-31
HU9303393D0 (en) 1994-03-28
KR100214905B1 (ko) 1999-08-02
GT199200028A (es) 1993-11-20
MX9202554A (es) 1992-11-01
NL300250I1 (nl) 2007-02-01
DE122006000066I2 (de) 2007-12-06
IS1611B (is) 1996-10-18
RO110499B1 (ro) 1996-01-30
IE72473B1 (en) 1997-04-23
CZ281403B6 (cs) 1996-09-11
IL102008A0 (en) 1992-12-30
NZ270673A (en) 1997-07-27
DE122006000066I1 (de) 2007-03-22
AP299A (en) 1994-01-14
CN1048492C (zh) 2000-01-19
EP0587723A1 (en) 1994-03-23
AP9200384A0 (en) 1992-07-31
DK0587723T3 (da) 1996-04-01
NO2007003I1 (no) 2007-03-26
US5807867A (en) 1998-09-15
DE9290063U1 (de) 1994-02-24
TW204349B (cg-RX-API-DMAC7.html) 1993-04-21
BR9206073A (pt) 1994-12-06
FI114475B (fi) 2004-10-29
HUT70151A (en) 1995-09-28
UY23422A1 (es) 1992-11-12
ES2084361T3 (es) 1996-05-01
WO1992021677A1 (en) 1992-12-10
FI935297A0 (fi) 1993-11-29
US6222038B1 (en) 2001-04-24
YU56492A (sh) 1995-03-27
HU217548B (hu) 2000-02-28
PT100546B (pt) 1999-12-31
EP0587723B1 (en) 1996-03-06
SK390692A3 (en) 1998-02-04
YU48995B (sh) 2003-04-30
RU2103269C1 (ru) 1998-01-27
ATE135006T1 (de) 1996-03-15
PL171379B1 (en) 1997-04-30
BG61694B1 (bg) 1998-03-31
IL102008A (en) 1995-12-08
CZ390692A3 (en) 1994-02-16
NL300250I2 (nl) 2007-03-01
JPH07285965A (ja) 1995-10-31
CA2102179C (en) 1998-10-27
JP2645225B2 (ja) 1997-08-25
IE921729A1 (en) 1992-12-02
DE69208877T2 (de) 1996-07-25

Similar Documents

Publication Publication Date Title
GR3019687T3 (en) Quinuclidine derivatives
GR3023621T3 (en) 3-Hydroxy-4-aryl-5-oxo-pyrazolin derivatives
NZ231461A (en) Quinuclidine derivatives
EP0746367A4 (en) EASY TO USE INTUBATOR
EP0440950A3 (en) Halogenallyl-azolyl derivatives
HU9203994D0 (en) Imidazo-pyridine derivatives
EP0519307A3 (en) Tetracyclic imidazodiazepines
EP0436333A3 (en) Azaoxindole derivatives
HU9202768D0 (en) Cyano-phenyl-pyrrole derivatives
EP0438690A3 (en) Substituted pyrazolin derivatives
ZA92278B (en) 3-quinuclidine derivatives
HU9202388D0 (en) Aryl-alkyl-amine derivatives
EP0520435A3 (en) Dc-89 derivatives
ZA922976B (en) 4-Aryl-3-heteroarylureidoquinoline derivatives
AP9100308A0 (en) Carboxymethylcyclopropane derivatives
HU9201889D0 (en) New cephem derivatives
GB2247886B (en) Azabicyclic derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
GB2262739B (en) Benzofuranylimidazole derivatives
HU9200011D0 (en) Trifluoro-methyl-1-carba(1-dethia)-cepheme derivatives
ZA92786B (en) Pyrimidinyl-and triazinylsalicyl-and-picolinylaldehyde derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
HU9200105D0 (en) Bipiridyl derivatives
EP0449346A3 (en) 4-piperidinyl-ergoline derivatives
GB9110611D0 (en) Pyrrolo-pyriding derivatives